Home / Pharmaceuticals / Neuroendocrine Tumor Treatment Market By Drug Class (Everolimus, Sunitinib, Lu-Dotatate, Lanreotide And Octreotide) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Neuroendocrine Tumor Treatment Market By Drug Class (Everolimus, Sunitinib, Lu-Dotatate, Lanreotide And Octreotide) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Published: Dec 2017 | Report Code: 58912-12-17

World Trade Center Health Program 2013 report on monitoring and treatment furnishes the distribution of neuroendocrine neoplasms in the human body which is 67.5% in gastrointestinal tracts and 25.3% in the bronchopulmonary tract. According to the World Health Organization global incidence rate of malignant neuroendocrine tumors is 0.2 per 100,000 persons. The drugs in the phase III clinical trials are developed as molecular targeted therapy which includes Sulfatinib, Vandetanib and Fotemustine. The radiopharmaceutical developed as somatostatin receptor antagonist is 177Lu-edotreotide PRRT.

Drug class segment for the scope of the report neuroendocrine tumor treatment market comprises drugs which are Everolimus, Lu-Dotatate, Sunitinib, Lanreotide and Octreotide. The product pipeline is also covered in the drug class segment highlighting the phase III drugs and tabular representation of phase II and I drugs.

Country cross sectional analysis of the drugs for neuroendocrine tumor treatment are covered in the geography section which is segmented as follows:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Performance of neuroendocrine tumor treatment market in the geographical segment is given by data forecast and market estimation.

Company profiles of the eminent players considered for the scope of the report gives important information regarding the existing product portfolio. Recent news coverage gives updates regarding the status of the drugs in pipeline tested for drug efficacy and safety in the clinical trials studies. Competitive landscape gives gist of the competitive nature of key players present in the neuroendocrine tumor treatment market. Top 3 countries and attractive investment proposition data gives industry investors the market trends present in the attractive markets. The market leaders engaged in manufacturing of drugs for the treatment of neuroendocrine tumors are Exelixis, Inc., Advanced Accelerator Applications, Dauntless Pharmaceuticals, Inc., Hutchinson Medipharma Limited, Ispen, Novartis AG, Progenics Pharmaceuticals, Inc. and Tarveda Therapeutics.

Neuroendocrine Tumor Treatment Market

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Neuroendocrine Tumor Treatment Market Portraiture
2.1.1. Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2016 (Value %)
2.1.2. Global Neuroendocrine Tumor Treatment Market, by Geography, 2016 (Value %)

Chapter 3. Neuroendocrine Tumor Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Neuroendocrine Tumor Epidemiology Data (Prevalence & Incidence)
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography
3.7. Top 3 Countries: Global Neuroendocrine Tumor Treatment Market, 2015-2025 (US$ Mn)
3.8. Competitive Landscape: Global Neuroendocrine Tumor Treatment Market, by Key Players, 2015-2025 (US$ Mn)

Chapter 4. Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2016
4.3. mTOR protein inhibitors (Everolimus)
4.4. Tyrosine kinase 3 inhibitors (Sunitinib)
4.5. Somatostatin receptor antagonists (Lu-Dotatate)
4.6. Growth hormone releasing factor antagonists (Lanreotide)
4.7. Somatostatin receptor agonists (Octreotide)
4.8. Pipeline Analysis
4.8.1. Phase III Drugs
4.8.1.1. Vandetanib
4.8.1.2. Fotemustine and Ipilimumab
4.8.1.3. 177Lu-edotreotide PRRT
4.8.1.4. Sulfatinib
4.8.2. Tabular Representation of Phase II and I Drugs

Chapter 5. Global Neuroendocrine Tumor Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. North America Neuroendocrine Tumor Treatment Market Analysis, 2015 – 2025
5.2.1. North America Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.2.2. North America Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Neuroendocrine Tumor Treatment Market Analysis, 2015 – 2025
5.3.1. Europe Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.3.2. Europe Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Neuroendocrine Tumor Treatment Market Analysis, 2015 – 2025
5.4.1. Asia Pacific Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.4.2. Asia Pacific Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.4.2.1. Japan
5.4.2.2. China
5.4.2.3. Rest of Asia Pacific
5.5. Latin America Neuroendocrine Tumor Treatment Market Analysis, 2015 – 2025
5.5.1. Latin America Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.5.2. Latin America Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa Neuroendocrine Tumor Treatment Market Analysis, 2015 – 2025
5.6.1. Middle East and Africa Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.6.2. Middle East and Africa Neuroendocrine Tumor Treatment Market, by Region, 2015 – 2025 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of Middle East and Africa

Chapter 6. Company Profiles
6.1. Advanced Accelerator Applications
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Dauntless Pharmaceuticals, Inc.
6.3. Exelixis, Inc.
6.4. Hutchinson Medipharma Limited
6.5. Ispen
6.6. Novartis AG
6.7. Progenics Pharmaceuticals, Inc.
6.8. Tarveda Therapeutics

List of Tables

TABLE 1 Global Neuroendocrine Tumor Treatment Market Portraiture
TABLE 2 Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 3 Global Neuroendocrine Tumor Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 4 North America Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 5 North America Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 12 Middle East And Africa Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East And Africa Neuroendocrine Tumor Treatment Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 14 Advanced Accelerator Applications: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Dauntless Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Exelixis, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Hutchinson Medipharma Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Ispen: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Progenics Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Tarveda Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

List of Figures

FIG. 1 Neuroendocrine Tumor Treatment: Market Segmentation
FIG. 2 Global Neuroendocrine Tumor Treatment Market Share, by Drug Class, 2016 (Value %)
FIG. 3 Global Neuroendocrine Tumor Treatment Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Everolimus Drug Market for Neuroendocrine Tumor Treatment, 2015 – 2025 (US$ Mn)
FIG. 7 Global Sunitinib Drug Market for Neuroendocrine Tumor Treatment, 2015 – 2025 (US$ Mn)
FIG. 8 Global Lu-Dotatate Drug Market for Neuroendocrine Tumor Treatment, 2015 – 2025 (US$ Mn)
FIG. 9 Global Lanreotide Drug Market for Neuroendocrine Tumor Treatment, 2015 – 2025 (US$ Mn)
FIG. 10 Global Octreotide Drug Market for Neuroendocrine Tumor Treatment, 2015 – 2025 (US$ Mn)
FIG. 11 U.S. Neuroendocrine Tumor Treatment Market, 2015– 2025 (US$ Mn)
FIG. 12 Canada Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 13 U.K. Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 14 Germany Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 15 Rest of Europe Neuroendocrine Tumor Treatment Market, 2015– 2025 (US$ Mn)
FIG. 16 Japan Neuroendocrine Tumor Treatment Market, 2015– 2025 (US$ Mn)
FIG. 17 China Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 18 India Neuroendocrine Tumor Treatment Market, 2015– 2025 (US$ Mn)
FIG. 19 Rest of Asia Pacific Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 20 Brazil Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 21 Mexico Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 22 Rest of Latin America Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 23 GCC Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 24 Rest of Middle East and Africa Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)

Based on drug class, the neuroendocrine tumor treatment market is categorized into:

  • mTOR protein inhibitors (Everolimus)
  • Tyrosine kinase 3 inhibitors (Sunitinib)
  • Somatostatin receptor antagonists (Lu-Dotatate)
  • Growth hormone releasing factor antagonists (Lanreotide)
  • Somatostatin receptor agonists (Octreotide)
  • Pipeline Analysis
    • Phase III Drugs
      • Vandetanib
      • Fotemustine and Ipilimumab
      • 177Lu-edotreotide PRRT
      • Sulfatinib
    • Tabular Representation of Phase II and I drugs

Neuroendocrine Tumor Treatment Market

The clinical manifestation of neuroendocrine tumor suggests that it is benign and sometimes malignant. It is asymptomatic in nature and usually occurs in the gastrointestinal tracts, pancreas, lungs and other parts of the body. The drug therapy employed for the treatment of neuroendocrine tumor consists of targeted drug therapy and somatostatin analogues. Targeted drug therapy comprises of molecules such as Everolimus and Sunitinib. They are gaining demand in the neuroendocrine tumor treatment as they are specifically blocking the growth of cancer by interfering with specific molecules that are engaged in the spread of cancer. The advantages of targeted drug therapy is that it has fewer side effects in comparison to chemotherapy drugs and suitable for long term treatment of chronic conditions. Somatostatin analogues such as Lu-Dotatate and Octreotide represent a futuristic trend in the treatment of neuroendocrine tumors. They are considered as a viable options for patients resistant to surgery and radiation therapy. The prominent players in neuroendocrine tumor treatment market are Advanced Accelerator Applications, Dauntless Pharmaceuticals, Inc., Exelixis, Inc., Hutchinson Medipharma Limited, Ispen, Novartis AG, Progenics Pharmaceuticals, Inc. and Tarveda Therapeutics.

For the purpose of this study, the global neuroendocrine tumor treatment market is categorized into the following regional and country specific markets:

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Neuroendocrine Tumor Treatment Market

Center for Disease Control and Prevention 2013 report has stated that the incidence rate of gastrointestinal neuroendocrine neoplasms in United States population is 1.4 cases per 100,000 persons. The well-developed diagnostic centers are able to detect asymptomatic neuroendocrine tumors and expedited drug clearance by USFDA contributes to the authority of neuroendocrine tumor treatment drugs market in North America. Europe market is influenced by the increasing number of patients suffering with pancreatic neuroendocrine tumors and supportive regulatory environment provided by European Medical Agency to drugs utilized for neuroendocrine tumors treatment.  Asia Pacific Neuroendocrine Tumor Society 2017 report states that the incidence rate of neuroendocrine tumors in Asian Pacific population to be around 1.51 per 100,000 persons. Increasing number of cancer treatment centers providing effective diagnosis and treatment are set to propel the Asia Pacific drugs for of neuroendocrine tumors treatment market.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients